Abstract：Objective: To investigate the effect of tiotropium and Shah Mette Lo Tikason on inflammatory factors and T lymphocytes in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Methods: Between February 2014 to February 2015 in our hospital respiratory outpatient department visits moderately severe plateau, 80 cases of COPD patients, all patients were randomly divided into two groups, the control group, 40 patients with routine western medicine treatment, the observation group 40 cases in the control group was given on the basis of the treatment. Consult for the occasional bromide combined salmeterol assigned for treatment. After 2 weeks treatment, and compared before and after treatment serum inflammatory factors [interleukin 8 (IL - 8) tumor necrosis factor alpha] (TNF alpha) in serum T lymphocytes (CD4 + CD8 +, CD4 + / CD8 +) and pulmonary function (FEV1, FVC FEV1 / FVC) level changes. Results: The clinical curative effect of observation group patients was significantly better than the control group patients (P < 0.05).Two groups after treatment in patients with IL - 8, TNF alpha value significantly reduced compared with before treatment (P < 0.05), the observation group after treatment in patients with IL - 8, TNF alpha value was significantly lower than the control group patients (P < 0.05).In the two groups after treatment in patients with serum CD4 + and CD4 + / CD8 + T lymphocytes was increased, the and falling CD8 + than before treatment (P < 0.05).Observation group of patients after treatment serum CD4 + and CD4 + / CD8 + T lymphocytes was higher than the control group, and CD8 + phase is lower (P < 0.05).Two groups of patients after two weeks of lung function were improved after treatment, improve is better than that of control group and observation group patients (P < 0.05). Conclusion: The seconds for the occasional bromide combined salmeterol calzone treatment period of COPD patients can effectively improve the patient's lung function, lower levels of inflammatory cytokines, enhance immunity.
孙静, 许亮. 噻托溴铵联合沙美特罗替卡松对中重度稳定期COPD患者T淋巴细胞炎性因子的影响[J]. 河北医学, 2017, 23(11): 1772-1775.
SUN Jing, et al. Effect of Tiotropium combined with Shah Mette Lo Tikason on T lymphocyte and Inflammatory Factors in patients with Moderate to Severe Stable COPD. HeBei Med, 2017, 23(11): 1772-1775.
[1] Fabbri LM, Hurd SS. Global strategy for the diagnosis, management and prevention of COPD: 2003 update[J].European Respiratory Journal, 2003, 22(1):1~2. [2] 侯小华,张秀华,曹书华.噻托溴铵联合舒利迭对老年中重度COPD患者临床症状积分及肺功能的影响[J].中国老年学,2012,32(7):1503~1504. [3] Magnussen H, Disse B, Rodriguezroisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD[J].New England Journal of Medicine, 2014, 371(14):1285~1294. [4] Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD[J].New England Journal of Medicine, 2014, 370(23):2201~2210. [5] 张梅香,邓年根,曹凌.联合吸入沙美特罗替卡松及噻托溴铵对COPD患者肺功能的改善作用[J].中国老年学,2012,32(10):2143~2145. [6] 顾文超,周新,袁亚平,等.吸入噻托溴铵对COPD患者肺功能和运动耐量的影响[J].上海交通大学学报(医学版),2008,28(9):1115~1118. [7] 姜锋,李晓明,张庆.国产噻托溴铵粉吸入剂对稳定期中重度COPD患者的临床疗效[J].中国老年学,2012,32(3):506~508. [8] Smith BM, Austin JH, Jr NJ, et al. Pulmonary emphysema subtypes on computed tomography: the MESA COPD study[J].American Journal of Medicine, 2014, 127(1):7~23. [9] 黄壮志,罗宁,谭世繁,等.BIPAP无创通气联合纳洛酮治疗COPD急性加重期合并肺性脑病临床观察[J].医学理论与实践,2015,28(1):53~54. [10] 陆燕芳.哌拉西林/他唑巴坦联合左氧氟沙星治疗COPD急性加重期的临床疗效及安全性分析[J].医学理论与实践,2015,28(22):3072~3074. [11] 谢勇.布地奈德联合特布他林雾化吸入救治COPD急性加重期临床效果[J].中国实用医药,2015,10(7):165~166. [12] Dickens C,Katon W, Blakemore A, et al.Complex interventions that reduce urgent care use in COPD: a systematic review with meta-regression[J].Respiratory Medicine, 2014, 108(3):426~437. [13] 王春艳.氧驱雾化吸入噻托溴铵联合盐酸氨溴索治疗老年COPD急性加重期的临床疗效[J].国际呼吸杂志,2015,35(11):815~818.
2017, Vol. 23 
冀公网安备13080202000677号